Literature DB >> 32524016

UNUSUAL PRESENTATIONS OF LMNA-ASSOCIATED LIPODYSTROPHY WITH COMPLEX PHENOTYPES AND GENERALIZED FAT LOSS: WHEN THE GENETIC DIAGNOSIS UNCOVERS NOVEL FEATURES.

Natalia Xavier S de Andrade, Suleyman Cem Adiyaman, Berna Demir Yuksel, Carla T Ferrari, Abdelwahab Jalal Eldin, Basak Ozgen Saydam, Canan Altay, Pratima Sharma, Nicole Bhave, Ann Little, Paul McKeever, Huseyin Onay, Sermin Ozkal, Mustafa Secil, Mustafa Nuri Yenerel, Baris Akinci, Elif A Oral.   

Abstract

OBJECTIVE: Lipodystrophy represents a group of rare diseases characterized by loss of body fat. While patients with generalized lipodystrophy exhibit near-total lack of fat, partial lipodystrophy is associated with selective fat loss affecting certain parts of the body. Although classical familial partial lipodystrophy (FPLD) is a well-described entity, recent reports indicate phenotypic heterogeneity among carriers of LMNA pathogenic variants.
METHODS: We have encountered 2 unique cases with complex phenotypes, generalized fat loss, and very low leptin levels that made the distinction between generalized versus partial lipodystrophy quite challenging.
RESULTS: We present a 61-year-old female with generalized fat loss, harboring the heterozygous pathogenic variant p.R541P (c.1622G>C) on the LMNA gene. The discovery of the pathogenic variant led to correct clinical diagnosis of her muscle disease, identification of significant heart disease, and a recommendation for the implantation of a defibrillator. She was able to start metreleptin based on her generalized fat loss pattern and demonstration of the genetic variant. Secondly, we report a 40-year-old Turkish female with generalized fat loss associated with a novel heterozygous LMNA pathogenic variant p.K486E (c.1456A>G), who developed systemic B cell follicular lymphoma.
CONCLUSION: Clinicians need to recognize that the presence of an LMNA variant does not universally lead to FPLD type 2, but may lead to a phenotype that is more complex and may resemble more closely generalized lipo-dystrophy. Additionally, providers should recognize the multisystem features of laminopathies and should screen for these features in affected patients, especially if the variant is not at the known hotspot for FPLD type 2.
Copyright © 2020 AACE.

Entities:  

Year:  2020        PMID: 32524016      PMCID: PMC7282159          DOI: 10.4158/ACCR-2019-0366

Source DB:  PubMed          Journal:  AACE Clin Case Rep        ISSN: 2376-0605


  15 in total

1.  Repression of nuclear lamin A and C gene expression in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells.

Authors:  B Stadelmann; E Khandjian; A Hirt; A Lüthy; R Weil; H P Wagner
Journal:  Leuk Res       Date:  1990       Impact factor: 3.156

2.  LMNA, encoding lamin A/C, is mutated in partial lipodystrophy.

Authors:  S Shackleton; D J Lloyd; S N Jackson; R Evans; M F Niermeijer; B M Singh; H Schmidt; G Brabant; S Kumar; P N Durrington; S Gregory; S O'Rahilly; R C Trembath
Journal:  Nat Genet       Date:  2000-02       Impact factor: 38.330

3.  Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy.

Authors:  Baris Akinci; Huseyin Onay; Tevfik Demir; Şenay Savas-Erdeve; Ramazan Gen; Ilgin Yildirim Simsir; Fatma Ela Keskin; Mehmet Sercan Erturk; Ayse Kubat Uzum; Guzin Fidan Yaylali; Nilufer Kutbay Ozdemir; Tahir Atik; Samim Ozen; Banu Sarer Yurekli; Tugce Apaydin; Canan Altay; Gulcin Akinci; Leyla Demir; Abdurrahman Comlekci; Mustafa Secil; Elif Arioglu Oral
Journal:  Metabolism       Date:  2017-04-27       Impact factor: 8.694

4.  Juvenile-onset generalized lipodystrophy due to a novel heterozygous missense LMNA mutation affecting lamin C.

Authors:  Nivedita Patni; Chao Xing; Anil K Agarwal; Abhimanyu Garg
Journal:  Am J Med Genet A       Date:  2017-07-07       Impact factor: 2.802

5.  In vivo and in vitro examination of the functional significances of novel lamin gene mutations in heart failure patients.

Authors:  N Sylvius; Z T Bilinska; J P Veinot; A Fidzianska; P M Bolongo; S Poon; P McKeown; R A Davies; K-L Chan; A S L Tang; S Dyack; J Grzybowski; W Ruzyllo; H McBride; F Tesson
Journal:  J Med Genet       Date:  2005-08       Impact factor: 6.318

6.  High yield of LMNA mutations in patients with dilated cardiomyopathy and/or conduction disease referred to cardiogenetics outpatient clinics.

Authors:  J Peter van Tintelen; Robert M W Hofstra; Hilga Katerberg; Tom Rossenbacker; Ans C P Wiesfeld; Gideon J du Marchie Sarvaas; Arthur A M Wilde; Irene M van Langen; Eline A Nannenberg; Anneke J van der Kooi; Marian Kraak; Isabelle C van Gelder; Dirk Jan van Veldhuisen; Yvonne Vos; Maarten P van den Berg
Journal:  Am Heart J       Date:  2007-09-14       Impact factor: 4.749

7.  Novel lamin A/C gene (LMNA) mutations in atypical progeroid syndromes.

Authors:  A B Csoka; H Cao; P J Sammak; D Constantinescu; G P Schatten; R A Hegele
Journal:  J Med Genet       Date:  2004-04       Impact factor: 6.318

Review 8.  The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.

Authors:  Rebecca J Brown; David Araujo-Vilar; Pik To Cheung; David Dunger; Abhimanyu Garg; Michelle Jack; Lucy Mungai; Elif A Oral; Nivedita Patni; Kristina I Rother; Julia von Schnurbein; Ekaterina Sorkina; Takara Stanley; Corinne Vigouroux; Martin Wabitsch; Rachel Williams; Tohru Yorifuji
Journal:  J Clin Endocrinol Metab       Date:  2016-10-06       Impact factor: 5.958

9.  Homozygous and Heterozygous Nuclear Lamin A p.R582C Mutation: Different Lipodystrophic Phenotypes in the Same Kindred.

Authors:  Renan Magalhães Montenegro; Aline Dantas Costa-Riquetto; Virgínia Oliveira Fernandes; Ana Paula Dias Rangel Montenegro; Lucas Santos de Santana; Alexander Augusto de Lima Jorge; Lia Beatriz de Azevedo Souza Karbage; Lindenberg Barbosa Aguiar; Francisco Herlânio Costa Carvalho; Milena Gurgel Teles; Catarina Brasil d'Alva
Journal:  Front Endocrinol (Lausanne)       Date:  2018-08-20       Impact factor: 5.555

10.  Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy.

Authors:  Elif A Oral; Phillip Gorden; Elaine Cochran; David Araújo-Vilar; David B Savage; Alison Long; Gregory Fine; Taylor Salinardi; Rebecca J Brown
Journal:  Endocrine       Date:  2019-02-25       Impact factor: 3.633

View more
  1 in total

1.  A 20-year Clinical and Genetic Neuromuscular Cohort Analysis in Lebanon: An International Effort.

Authors:  Andre Megarbane; Sami Bizzari; Asha Deepthi; Sandra Sabbagh; Hicham Mansour; Eliane Chouery; Ghassan Hmaimess; Rosette Jabbour; Cybel Mehawej; Saada Alame; Abeer Hani; Dana Hasbini; Ismat Ghanem; Salam Koussa; Mahmoud Taleb Al-Ali; Marc Obeid; Diana Bou Talea; Gerard Lefranc; Nicolas Lévy; France Leturcq; Stephany El Hayek; Valérie Delague; J Andoni Urtizberea
Journal:  J Neuromuscul Dis       Date:  2022
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.